May 9 |
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
|
May 9 |
Takeda Pharmaceutical Non-GAAP EPS of ¥484, revenue of ¥4263.8B; initiates FY24 outlook
|
May 9 |
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
|
May 8 |
Nikkei Up 0.2%, Led by Banks, Insurers
|
May 8 |
Takeda Pharmaceutical Q4 Earnings Preview
|
May 8 |
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
|
May 7 |
New house bill to extend COVID-era telehealth flexibilities
|
Apr 29 |
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|
Apr 26 |
Bristol, Sanofi, Takeda gain positive CHMP recommendations
|
Apr 26 |
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|